Clinical Trials
2 trialsNCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT06199271 2024-01-22
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
Sichuan University
Phase 2 Not yet recruiting